Evidence map›Paper›PMID 30501530›Full record

ReviewExpert review of anti-infective therapy2019

Current research toward optimizing dosing of first-line antituberculosis treatment.

Helen McIlleron, Maxwell T Chirehwa

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of anti-infective therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Pooled it
  2. Pooled it
  3. Trial
  4. Clinical Outcomes in Children With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  12. Review
  13. Article
  14. Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Helen McIllerona Division of Clinical Pharmacology, Department of Medicine , University of Cape Town , Cape Town , South Africa.
Maxwell T Chirehwaa Division of Clinical Pharmacology, Department of Medicine , University of Cape Town , Cape Town , South Africa.
University of Cape Town · ZA

Funding

Optimal dosing of 1st line antituberculosis and antiretroviral drugs in childrenR01HD069175 · NICHD · UNIVERSITY OF CAPE TOWN · PI MCILLERON, HELEN · 2011 to 2018
$1.8M
Pharmacometric optimization of second line drugs for MDR tuberculosis treatmentR01AI116155 · NIAID · UNIVERSITY OF CAPE TOWN · PI GUMBO, TAWANDA, MCILLERON, HELEN · 2015 to 2019
$1.7M
NIAID NIH HHS R01 AI116155NICHD NIH HHS R01 HD069175Wellcome Trust 206379/Z/17/Z
6 · The paper itself

Abstract

introductionDrug concentrations in tuberculosis patients on standard regimens vary widely with clinically important consequences. Areas covered: We review the available literature identifying factors correlated with pharmacokinetic variability of antituberculosis drugs. Based on population pharmacokinetic models and the weight, height, and sex distributions in a large data base of African tuberculosis patients, we propose simplified weight-based doses of the available fixed dose combination(FDC) for adults with drug susceptible tuberculosis. Emerging studies will support optimized weight-based dosing for children. Other sources of important pharmacokinetic variability include genetic variants, drug-drug interactions, formulation quality, and methods of preparation and administration. Expert commentary: Optimized weight band-based dosing will result in more equitable distribution of drug exposures by weight. The use of high doses of isoniazid in patients with drug-resistant tuberculosis would be safer and more effective if a feasible test was developed to allow stratified dosing according to acetylator type. There is an urgent need for more suitable formulations of many second-line drugs for children. The adoption of new technologies and efficient FDC design may allow further advances for patients and treatment programs. Lastly, current efforts to ensure adequate quality of antituberculosis drug products are not preventing the use of substandard products to treat patients with tuberculosis.

Indexed as

Models, BiologicalAdultAnimalsAntitubercular AgentsChildDose-Response Relationship, DrugDrug InteractionsFemaleHumansMaleTuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsEthambutolpharmacogeneticpharmacokineticpyrazinamiderifampin

Identifiers

PMID30501530
PMCPMC6364307
OpenAlexW2902621929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.